Log in | Register

De-escalation of antimicrobial treatment in neutropenic patients with severe sepsis: results from an observational study

Djamel Mokart| Géraldine Slehofer| Jérôme Lambert| Antoine Sannini| Laurent Chow-Chine| Jean-Paul Brun| Pierre Berger| Ségolène Duran| Marion Faucher| Jean-Louis Blache| Colombe Saillard| Norbert Vey| Marc Leone
Original Article
Volume 40, Issue 1 / January , 2014

Pages 41 - 49

Abstract

Background

In severe sepsis, guidelines recommend de-escalating the empirical antimicrobial treatment as soon as the microbiological results are available. We aimed to determine the rate of de-escalation of the empirical antimicrobial treatment in neutropenic patients with severe sepsis. The characteristics of antimicrobial treatment associated with de-escalation and its impact on short- and long-term survival were also determined.

Methods

In the intensive care unit (ICU) of a cancer referral center, we prospectively collected observational data related to the antimicrobial management in neutropenic patients who developed severe sepsis and were admitted to ICU for at least 48 h. De-escalation of antimicrobial therapy consisted either of deleting one of the empirical antibiotics of a combined treatment, or, whenever possible, to use a betalactam antibiotic with a narrower spectrum of activity. Multivariate logistic regression was conducted to determine the factors associated with de-escalation, while a Cox proportional hazards model with a time-dependent covariate was fitted to assess the effect of de-escalation on 30-day survival. Finally 1-year survival after ICU discharge was compared across de-escalation groups.

Results

Cumulative incidence of de-escalation of the empirical antimicrobial treatment among the 101 patients of the cohort was 44 %, [95 % confidence interval (CI) 38–53 %], including 30 (68 %) patients with ongoing neutropenia. A microbiological documentation was available in 63 (63 %) patients. Factors associated with de-escalation were the adequation of the empirical antimicrobial treatment in ICU [OR = 10.8 (95 % CI 1.20–96)] for adequate documented treatment versus appropriate empirical treatment, the compliance with guidelines regarding the empirical choice of the anti-pseudomonal betalactam [OR = 10.8 (95 % CI 1.3–89.5)]. De-escalation did not significantly modify the hazard of death within the first 30 days [HR = 0.51 (95 % CI 0.20–1.33)], nor within 1 year after ICU discharge [HR = 1.06 (95 % CI 0.54–2.08)].

Conclusion

Our data suggest that, in ICU, de-escalation of the empirical antimicrobial treatment is frequently applied in neutropenic cancer patients with severe sepsis. No evidence of any prognostic impact of this de-escalation was found.

Keywords

References

  1. Dellinger RP, Levy MM, Rhodes A et al (2013) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:165–228
  2. Kollef MH, Micek ST (2005) Strategies to prevent antimicrobial resistance in the intensive care unit. Crit Care Med 33:1845–1853
    • View reference on PubMed
    • View reference on publisher's website
  3. Shorr AF (2009) Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit. Crit Care Med 37:1463–1469
    • View reference on PubMed
    • View reference on publisher's website
  4. Leone M, Bourgoin A, Cambon S, Dubuc M, Albanese J, Martin C (2003) Empirical antimicrobial therapy of septic shock patients: adequacy and impact on the outcome. Crit Care Med 31:462–467
    • View reference on PubMed
    • View reference on publisher's website
  5. Leone M, Garcin F, Bouvenot J et al (2007) Ventilator-associated pneumonia: breaking the vicious circle of antibiotic overuse. Crit Care Med 35:379–385
    • View reference on PubMed
    • View reference on publisher's website
  6. Rello J, Vidaur L, Sandiumenge A et al (2004) De-escalation therapy in ventilator-associated pneumonia. Crit Care Med 32:2183–2190
    • View reference on PubMed
  7. Heenen S, Jacobs F, Vincent JL (2012) Antibiotic strategies in severe nosocomial sepsis: why do we not de-escalate more often? Crit Care Med 40:1404–1409
    • View reference on PubMed
    • View reference on publisher's website
  8. Talpaz M, Shah NP, Kantarjian H et al (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354:2531–2541
    • View reference on PubMed
    • View reference on publisher's website
  9. Vanneman M, Dranoff G (2012) Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 12:237–251
    • View reference on PubMed
    • View reference on publisher's website
  10. Song JU, Suh GY, Park HY et al (2012) Early intervention on the outcomes in critically ill cancer patients admitted to intensive care units. Intensive Care Med 38:1505–1513
  11. Legrand M, Max A, Schlemmer B, Azoulay E, Gachot B (2011) The strategy of antibiotic use in critically ill neutropenic patients. Ann Intensive Care 1:22
    • View reference on PubMed
    • View reference on publisher's website
  12. Freifeld AG, Bow EJ, Sepkowitz KA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis 52:427–431
    • View reference on PubMed
    • View reference on publisher's website
  13. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864–874
    • View reference on publisher's website
  14. Bernard GR, Artigas A, Brigham KL et al (1994) The American-European consensus conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 149:818–824
    • View reference on PubMed
    • View reference on publisher's website
  15. Knaus WA, Draper EA, Wagner DP, Zimmerman JE (1985) Prognosis in acute organ-system failure. Ann Surg 202:685–693
    • View reference on PubMed
    • View reference on publisher's website
  16. Le Gall JR, Lemeshow S, Saulnier F (1993) A new simplified acute physiology score (SAPS II) based on a European/north American multicenter study. JAMA 270:2957–2963
    • View reference on PubMed
    • View reference on publisher's website
  17. Vincent JL, de Mendonça A, Cantraine F et al (1998) Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine. Crit Care Med 26:1793–1800
    • View reference on PubMed
    • View reference on publisher's website
  18. Azoulay E, Mokart D, Lambert J et al (2010) Diagnostic strategy for hematology and oncology patients with acute respiratory failure: randomized controlled trial. Am J Respir Crit Care Med 182:1038–1046
    • View reference on PubMed
    • View reference on publisher's website
  19. Azoulay E, Schlemmer B (2006) Diagnostic strategy in cancer patients with acute respiratory failure. Intensive Care Med 32:808–822
  20. Meunier F, Lukan C (2008) The first European conference on infections in leukaemia—ECIL1: a current perspective. Eur J Cancer 44:2112–2117
    • View reference on PubMed
    • View reference on publisher's website
  21. Buchheidt D, Bohme A, Cornely OA et al (2003) Diagnosis and treatment of documented infections in neutropenic patients–recommendations of the infectious diseases working party (AGIHO) of the German society of hematology and oncology (DGHO). Ann Hematol 82(Suppl 2):S127–S132
    • View reference on PubMed
    • View reference on publisher's website
  22. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D (2003) Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 115:529–535
    • View reference on PubMed
    • View reference on publisher's website
  23. Mikulska M, Akova M, Averbuch D, Klyasova G, Livemore D, Orasch C et al. 4th European Conference on Infections in Leukemia. http://www.ebmt.org/Contents/Resources/Library/ECIL/Documents/ECIL4%202011%20Bacterial%20resistance%20in%20Haematology.pdf. 14-2-2012
  24. Trecarichi EM, Tumbarello M, Spanu T et al (2009) Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect 58:299–307
    • View reference on PubMed
    • View reference on publisher's website
  25. Tumbarello M, Spanu T, Sanguinetti M et al (2006) Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother 50:498–504
    • View reference on PubMed
    • View reference on publisher's website
  26. Safdar A, Rolston KV (2007) Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. Clin Infect Dis 45:1602–1609
    • View reference on PubMed
    • View reference on publisher's website
  27. Kollef MH (2006) Providing appropriate antimicrobial therapy in the intensive care unit: surveillance vs. de-escalation. Crit Care Med 34:903–905
    • View reference on PubMed
    • View reference on publisher's website
  28. Morel J, Casoetto J, Jospe R et al (2010) De-escalation as part of a global strategy of empiric antibiotherapy management. A retrospective study in a medico-surgical intensive care unit. Crit Care 14:R225
    • View reference on PubMed
    • View reference on publisher's website
  29. Karvunidis T, Chvojka J, Lysak D et al (2012) Septic shock and chemotherapy-induced cytopenia: effects on microcirculation. Intensive Care Med 38:1336–1344
  30. Mokart D, van Craenenbroeck T, Lambert J et al (2012) Prognosis of acute respiratory distress syndrome in neutropenic cancer patients. Eur Respir J 40:169–176
    • View reference on PubMed
    • View reference on publisher's website
  31. Xu XJ, Tang YM, Liao C et al (2013) Inflammatory cytokine measurement quickly discriminates gram-negative from gram-positive bacteremia in pediatric hematology/oncology patients with septic shock. Intensive Care Med 39:319–326
  32. Depuydt P, Benoit D, Vogelaers D et al (2006) Outcome in bacteremia associated with nosocomial pneumonia and the impact of pathogen prediction by tracheal surveillance cultures. Intensive Care Med 32:1773–1781
  33. Azoulay E, Mokart D, Rabbat A et al (2008) Diagnostic bronchoscopy in hematology and oncology patients with acute respiratory failure: prospective multicenter data. Crit Care Med 36:100–107
    • View reference on PubMed
    • View reference on publisher's website
  34. Burghi G, Lemiale V, Seguin A et al (2011) Outcomes of mechanically ventilated hematology patients with invasive pulmonary aspergillosis. Intensive Care Med 37:1605–1612
  35. Silva BN, Andriolo RB, Atallah AN, Salomao R (2013) De-escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shock. Cochrane Database Syst Rev 3:CD007934
    • View reference on PubMed

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement